Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher

by Jayson Derrick

February 20, 2015 11:14 AM | 27 seconds read | Make a Comment

Shares of

Novo Nordisk A/SNVO

were trading higher by more than four percent Friday morning after the company

announced positive results from a phase 2 FDA trial. Novo Nordisk announced that it "has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks."

Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In: News Diabities Novo Nordisk OG217SC Phase 2

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Benzinga.com on devices